Patient-derived glioblastoma stem cells respond differentially to targeted therapies.
about
PIK3CB/p110β is a Selective Survival Factor for Glioblastoma.Radioresistance of mesenchymal glioblastoma initiating cells correlates with patient outcome and is associated with activation of inflammatory program.Glioblastoma research: US and international networking achievements.Casein Kinase 1 Epsilon Regulates Glioblastoma Cell Survival
P2860
Patient-derived glioblastoma stem cells respond differentially to targeted therapies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Patient-derived glioblastoma stem cells respond differentially to targeted therapies.
@en
Patient-derived glioblastoma stem cells respond differentially to targeted therapies.
@nl
type
label
Patient-derived glioblastoma stem cells respond differentially to targeted therapies.
@en
Patient-derived glioblastoma stem cells respond differentially to targeted therapies.
@nl
prefLabel
Patient-derived glioblastoma stem cells respond differentially to targeted therapies.
@en
Patient-derived glioblastoma stem cells respond differentially to targeted therapies.
@nl
P2093
P2860
P356
P1433
P1476
Patient-derived glioblastoma stem cells respond differentially to targeted therapies.
@en
P2093
Gary R Simonds
Pratik Kanabur
Robert G Gourdie
Scott S Verbridge
Sujuan Guo
P2860
P304
86406-86419
P356
10.18632/ONCOTARGET.13415
P407
P577
2016-11-16T00:00:00Z